Matthew Dennis

For the second time in two months, the UK approved a new treatment for Alzheimer's disease, but simultaneously ruled that its "relatively small benefit" is too costly for use on the NHS.

Alto Neuroscience lost more than half its value in premarket trading on Wednesday after the company reported that a Phase IIb study of its experimental

Roche's Vabysmo continued to be the company's largest sales driver in the third quarter, although the pace of growth for the eye medicine is appearing to lose some steam.

Just days after Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo gained FDA approval for use in adults 18 through 59 years of age, GSK

Merck & Co. said Thursday that Keytruda gained two new gynecologic cancer approvals from European regulators, marking the 29th and 30th indications for the anti-PD-1 therapy in the EU.

Sanofi's latest quarterly results got a fillip not only from its top-seller Dupixent, but also from its vaccines portfolio, including the respiratory syncytial virus (RSV) preventative Beyfortus.

GSK will invest up to $800 million at its site in Marietta, Pennsylvania to create new facilities dedicated to producing medicines and vaccines , doubling its its capacity.

Antitrust regulators in Europe have set a provisional deadline of December 6 to rule on the takeover of Catalent by Novo Nordisk's controlling shareholder Novo Holdings.

New results showed that Viking Therapeutics' oral version of the dual GLP-1/GIP receptor agonist VK2735 led to weight loss of up to 8.2% after four weeks, building on promising data from earlier in the year.

Merus is facing a delay in securing approval of its first Biclonic product after the FDA extended its review of zenocutuzumab to February 4 next year.